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Background/aim: The effectiveness of inhaled corticosteroids (ICSs) in cystic fibrosis (CF) is controversial. The aim of this study was
to investigate the effect of an ICS on bronchial hyperreactivity (BHR), oxidative status, and clinical and inflammatory parameters in CF
patients.
Materials and methods: CF patients were randomized to receive either 2 mg/day nebulized budesonide or 0.9% normal saline as
placebo for 8 weeks.
Results: Twenty-nine CF patients (mean age: 10.5 ± 2.9 years) were enrolled in the study. There was no statistically significant difference
between the two groups at the end of 8 weeks in terms of symptoms, pulmonary function, BHR, oxidative burst, hs-CRP, or ESR.
Although there was a significant decrease in malondialdehyde levels in both groups, there was no difference between the two groups.
Percentage of neutrophils in the sputum of patients decreased in the budesonide group (P = 0.006). Although sputum IL-8 levels
significantly increased in both groups, there was no statistically significant difference between the two groups.
Conclusion: Although there was a significant decrease in the percentage of neutrophils in sputum with budesonide, 8 weeks of 2 mg/
day nebulized budesonide was not effective in terms of BHR, oxidative status, or clinical and other inflammatory parameters in children
with CF.
Key words: Antiinflammatory treatment, children, cystic fibrosis, glucocorticoids, inhalation

1. Introduction
Cystic fibrosis (CF) is a lung disease characterized by
a vicious cycle of airway obstruction, chronic bacterial
infection, and neutrophil-dominated airway inflammation
(1,2). Local pulmonary inflammation in CF starts early
in life and, if untreated, this inflammatory process can
irreversibly damage the airways, leading to bronchiectasis
and respiratory failure. To control the inflammation
at the early stages may limit the destructive effect of
inflammation, delay the pulmonary deterioration, and
decrease the morbidity and mortality (3). In CF, the
antiinflammatory effects of oral corticosteroids, ibuprofen,
and macrolide antibiotics have been studied (4–6).
However, the efficacy and safety of inhaled corticosteroids
(ICSs) are still controversial. Some studies suggest that
ICS therapy in CF may improve lung function, reduce
bronchial hyperreactivity (BHR), improve symptoms
* Correspondence: zeynepsedau@yahoo.com
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like cough and dyspnea, and reduce airway inflammation
(7–9). In contrast, some studies did not show any
improvement in clinical status or lung function (10,11). A
recent metaanalysis about ICSs for CF stated that evidence
from trials has been insufficient to establish whether
ICSs are beneficial in CF, but withdrawal in those already
taking them has been shown to be safe (12). Despite the
controversies, ICSs are widely used in CF patients as an
antiinflammatory medication. They are better tolerated
and have less side effects than oral corticosteroids (13).
Therefore, new multifaceted studies are needed to
investigate the effect of ICSs in the treatment of children
with CF. The aim of the present study was to investigate
the effect of an ICS on oxidative status and clinical and
inflammatory parameters as well as BHR in CF patients.
We hypothesized that ICSs are effective for treatment of
these parameters in CF.
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2. Materials and methods
2.1. Study population
CF patients with two abnormal sweat tests (chloride
concentration > 60 mEq/L) were recruited from the
pediatric pulmonology clinic of Marmara University
Hospital. Inclusion criteria: All CF patients over 6 years
of age attending the CF clinic. Exclusion criteria: systemic
steroid use within the previous 6 months, ICS use within
the previous 2 months, pulmonary exacerbation within the
previous 4 weeks, history of asthma and atopy in the family
and the child, and inability to perform spirometry. All of
the CF patients were receiving concomitant nebulized
bronchodilator and DNAse treatment, while those with
Pseudomonas colonization were also receiving nebulized
antibiotics.
2.2. Study design
The study was prospectively designed and the protocol
was approved by the Marmara University Medical School
Ethics Committee (MAR-YÇ-2006-0034) and parental
informed consent was obtained for each patient.
At the first visit, symptoms, physical examination
findings and pulmonary function test (PFT) with
bronchodilator response were recorded. Blood samples

and induced sputum were collected. One week later, a
methacholine challenge test (MCT) was performed. After
generating a random number row, patients with even and
odd numbers were randomized to receive either 2 mg/day
nebulized budesonide (2 × 2 cc) or 0.9% normal saline
(2 × 2 cc) as placebo for 8 weeks by a second investigator
who was blinded to the clinical status of the patient.
The study was designed as a single-blinded study due to
nonavailability of 0.9% normal saline in a similar vial
as budesonide. At the end of 8 weeks, patients were reevaluated for clinical and laboratory parameters and the
MCT was performed 1 week later (Figure 1).
2.3. Clinical and radiological scores
Clinical status of the patients and the severity of the disease
were evaluated by Shwachman–Kulczycki (S-K) (14) and
Brasfield scores (15).
Chest radiographs were taken from all patients at
the beginning of the study. High resolution computed
tomography (HRCT) was obtained for patients who
had not undergone it in the previous 6 months. Chest
radiographs and HRCTs were scored by a blind radiologist
according to the Brasfield clinical scoring system (15) and
CT scoring system used by Helbich et al. (16), respectively.

Screening

Personal and family history, previous laboratory results and treatment
modalities obtained from patient files

1st visit

Symptom scoring, physical examination, PFT, bronchodilator response
Scoring of the high resolution computed tomographies
Randomization of the patients to drug/placebo groups
Blood and induced sputum collection!

1 Week

2nd visit

Physical examination, SpO2, PFT, methacholine challenge test, initiation
of drug/placebo

8 Weeks
3rd visit

Physical examination, SpO2, PFT, bronchodilator response, blood and
induced sputum collection, symptom scoring !

1 Week
4th visit

Physical examination, SpO2, PFT, methacholine challenge test

Figure 1. Study plan.
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Cough, wheezing, dyspnea, and sputum amount and
color were scored by the patients using a subjective 0–3
scoring system, where 0 = none, 1 = mild, 2 = moderate,
and 3 = severe. Symptoms were separately scored with
presence and increasing intensity, with a possible total
score of 0 if there are no symptoms and 15 if patients have
severe symptoms and green sputum (17).
2.4. Sputum induction
Sputum samples of the patients were obtained by sputum
induction (18) with the inhalation of an aerosol hypertonic
saline (3% NaCl) solution through the reservoir of
ultrasonic nebulizer (UN - 808 Sigma Medical Supplies
Corp. Taipei, Taiwan). The sputum induction procedure
was stopped if the patient had symptoms or wheezing was
detected on physical examination or ≥20% decrease was
detected in FEV1. If any of these occurred, the patient was
administered inhaled salbutamol and observed until FEV1
recovered to 10% of baseline.
Obtained sputum samples were processed within 2
h. After processing, the samples were divided into two.
One sample was examined immediately in terms of total
white blood cell (WBC) count and percent of neutrophils
(LH 750 Coulter, Brea, CA, USA) while the other sample
was stored at –80 °C for TNF-α and IL-8 measurement
by chemiluminescence method (DPC Immulite 1000,
Siemens, USA).
2.5. Pulmonary function tests (PFTs)
Vital capacity and flow rates were measured by spirometry
(MIR Srl Spirobank, Italy, No. 23432) according to the
criteria of the American Thoracic Society (ATS) while
patients were awake and in the seated position (19).
Spirometry results were reported as the ratio of percentage
of normal values based on age, sex, and height. The best
value of a minimum of the three adequate measurements
was taken. Reference values obtained by Knudson et al.
(20) were used.
2.6. Methacholine challenge test
The MCT was performed by using the five-breath dosimeter
protocol (21) at least 12 h after the last dose of inhaled β2
agonist. Solution of methacholine chloride (Provocholine;
Methapharm Inc, Brantford, ON, Canada) was used.
Aerosols were generated by a nebulizer (DeVilbiss 646
nebulizer, automatic inspirium-sensored dosimeter zAn
- 200 ProvAir, Spiromed). After inhalation of an isotonic
saline solution, doubling concentrations (0.0125–32 mg⁄
mL) of methacholine were administered. The response
to methacholine was measured as the change in the
percentage of FEV1 of the initial value. The concentration
of methacholine solution at which FEV1 fell by 20% of
postsaline value (PC20) was obtained by interpolation of
the log dose-response curve. BHR was defined as a PC20 of
≤8 mg/mL (22).
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2.7. Blood samples
Blood samples were obtained between 0800 and 0930
after 8 h fasting and immediately centrifuged at 3500
× g for 10 min and the serum was stored at –80 °C until
assayed. Blood samples were obtained for high sensitive
C-reactive protein (hs-CRP), erythrocyte sedimentation
rate (ESR), total blood count, malondialdehyde (MDA),
and monocyte oxidative burst measurement. To evaluate
inflammatory status, hs-CRP, ESR, and oxidative burst
of monocytes were measured while to evaluate oxidative
damage intensity, plasma concentrations of MDA were
measured.
MDA measurements were done with high-performance
liquid chromatography (HPLC) (Agilent 1100) and hs-CRP
immunoturbidometrically (Modular P, Roche Diagnostics,
Mannheim, Germany). Respiratory burst of monocytes
was measured by luminal-enhanced chemiluminescence
(Minilumat, Berthold LB, Bad Wildbad, Germany) before
and after phorbol-myristate acetate (PMA) induction.
2.8. Statistical analysis
The statistical analysis was carried out with Statistical
Package for the Social Sciences (SPSS) 11.0 for Windows.
The data were not distributed normally and described as
median and interquartile ranges. While comparing the
two groups receiving drug or placebo, categorical variables
were analyzed by chi-square test and continuous variables
were analyzed using Wilcoxon’s test. A P < 0.05 was
regarded as statistically significant.
3. Results
Thirty-two CF patients were enrolled in the study. Three
patients were excluded during the study: two patients were
diagnosed and treated for allergic bronchopulmonary
aspergillosis and the other patient was excluded up on her
parents’ request. Therefore, the study was concluded with
29 patients and statistical analysis was carried out on the
results of these 29 patients. All three patients who were
excluded were in the placebo group.
3.1. Comparison of baseline data
Mean age was 10.5 ± 2.9 years and mean follow-up
duration was 4.9 ± 3.4 years. There was no statistically
significant difference between the two groups in terms
of demographic features, clinical status, symptom scores,
inflammatory markers, pulmonary function tests,
bronchodilator response, or MCT results at baseline;
however, the rate of Pseudomonas colonization and total
WBC count in the sputum were significantly different
(Table 1).
3.2. Comparison of budesonide and placebo treatments
There were no statistically significant differences between
the two groups in terms of clinical symptoms or PFT
measurements at the end of 8 weeks (Table 2). Twenty-four
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Table 1. Demographic features, clinical status, PFT, and laboratory test results of the patients at baseline (mean ± SD/
median (25th–75th percentiles)).
Budesonide
(n = 17)

0.9% normal saline
(n = 12)

P

Female/male (n)

12/5

8/4

0.82

Age (years)

11.3 ± 3.0

9.5 ± 2.74

0.10

S-K score

76.15 ± 15.83

85.63 ± 14.25

0.18

Brasfield score

13.31 ± 6.61

12.25 ± 9.68

0.77

HRCT score

14 (6.5–19.5)

6 (4–15)

0.10

Symptom score

2.5 (0.3–5.0)

3.0 (1.0–4.0)

0.95

MDA (ng/dL)

1.7 (1.6–1.9)

1.8 (1.4–1.9)

0.92

ΔAU/mL

109,399
(64,908–520,201)

74,967
(14,494–648,110)

0.59

hs-CRP

1.6 (0.5–7.4)

0.6 (0.2–1.9)

0.11

ESR

20.5 (12.5–34.5)

21 (7–22.7)

0.41

8576.92 ± 4095.76

7228.57 ± 1285.45

0.55

Sputum WBC count (10 /µL)

0.8 (0.6–4)

0.3 (0.2–0.7)

0.01

FVC (%)

81.66 ± 15.37

87.84 ± 18.79

0.34

FEV1 (%)

84.83 ± 18.16

92.94 ± 18.18

0.25

FEF25–75 (%)

91.47 ± 32.01

98.03 ± 24.62

0.56

Pseudomonas colonization n (%)

8 (47)

1 (8.3)

0.01

Blood WBC count
3

patients were able perform the methacholine challenge
test both at the beginning and at the end of the study.
The number of patients with BHR decreased following
budesonide treatment in contrast to the placebo group
(Table 2); however, there was no concomitant decrease in
symptoms or inflammatory mediators except MDA, which
decreased in both groups at the end of 8 weeks without a
significant difference between the two groups. There was
no statistically significant difference in PC20FEV1 values
before and after budesonide/placebo treatment (Table 2).
Following treatment, there were no statistically
significant differences in each group or between the two
groups in terms of oxidative burst of monocytes, hs-CRP,
ESR results, or sputum TNF-α levels (Table 2).
Both WBC and percent of neutrophils (Figure 2) in
sputum decreased in the budesonide group, while there
was no decrease in the placebo group (Table 2). At the end
of 8 weeks, sputum IL-8 levels increased in both groups,
only the increase in the budesonide group was statistically
significant, and there was no statistically significant
difference between the two groups (Figure 3).

4. Discussion
In this study, we evaluated the efficacy of 8 weeks of
nebulized budesonide in CF patients and found that this
treatment was not effective for improving symptoms, PFT,
BHR, and inflammatory parameters, except the WBC
count and percent of neutrophils in sputum, which were
significantly decreased in the budesonide group.
ICSs are widely used in CF patients in many countries.
Konstan et al. reported that the use of ICSs in CF patients
significantly increased from 16% to 49.3% from 1995
to 2005 (23). The use of ICSs may be justified as a form
of symptomatic prophylaxis for those with recurrent
wheezing or CF asthma (24), but they are also prescribed
by many clinicians purely for their perceived benefit as an
antiinflammatory agent (25). In this study, we aimed to
investigate the effect of an ICS on BHR, oxidative status,
and clinical and inflammatory parameters in CF patients.
FEV1 measurement is the most widely used method to
evaluate the efficacy of antiinflammatory drugs in CF (26).
The PFT results were not significantly different following
budesonide treatment in our study. This result was similar
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Table 2. Blood and sputum laboratory test and PFT results of the patients before and after treatment (mean ± SD/median(25th–75th
percentiles)).
Budesonide
(n = 17)

p

0.9% normal saline
(n = 12)

P

P1

2.5
(0.0–4.0)

0.43

0.59

1.8
(1.4–1.9)

1.1
(0.9–1.2)

0.01

0.68

0.83

74,967.0
(14,494.2–648,110.2)

176,867.8
(31,732.6–639,216.2)

1.00

0.91

1.0
(0.1–4.6)

0.23

0.6
(0.2–1.9)

0.3
(0.2–4.3)

0.93

0.84

20.5
(12.2–34.5)

15.5
(6.7–30.7)

0.08

21
(7.0–22.7)

20
(7.7–32.7)

0.40

0.84

Sputum WBC count
(103/µL)

0.8
(0.6–4.0)

0.6
(0.4–0.8)

0.02

0.3
(0.2–0.7)

0.4
(0.1–0.5)

0.47

0.06

Percentage of neutrophils
in the sputum

68.9
(19.9–87.6)

18.6
(13.9–36.7)

0.01

37.4
(17.6–51.1)

28.2
(10.9–47.9)

0.50

0.59

Sputum
TNF-α

27.7
(21.8–30.2)

26.4
(24.0–28.2)

0.96

26.7
(20.6–27.6)

26.5
(22.6–44.2)

0.10

0.96

Sputum
IL-8

2263.0
(149.6 –4169.0)

6261.5
(767.0 –13440)

0.04

23.3
(14.9 –6853.0)

3565.5
(755.0 –6081.2)

0.35

0.44

FVC (%)

81.6 ± 15.3

82.2 ± 21.6

0.84

87.8 ± 18.7

84.7 ± 19.4

0.36

0.75

FEV1 (%)

84.8 ± 18.1

81.9 ± 23.3

0.32

92.9 ± 28.1

88.6 ± 19.8

0.23

0.43

FEF25–75 (%)

91.4 ± 32.0

79.8 ± 31.8

0.03

98.0 ± 24.6

91.6 ± 29.8

0.47

0.32

BHR n (%)

8 (47)

6 (35)

0.73

6 (50)

8 (67)

0.68

0.70

PC20FEV1

3.5 (2.4–6.8)

2.9 (1.1–11.6)

1.00

1.5 (0.7–8.3)

1.6 (0.4–5.8)

0.40

0.23

Before

After

Before

After

Symptom score

2.5
(0.3–5.0)

3.0
(2.0–4.0)

0.88

3.0
(1.0–4.0)

MDA (ng/dL)

1.7
(1.6–1.9)

1.1
(1.0–1.4)

<0.001

ΔAUC/mL

109,399.0
(64,908.5–520,201.2)

90,714.2
(33,323.6715,955.2)

hs-CRP

1.6
(0.5–7.4)

ESR

P1 : P values of the comparison of the second measurements

%
100
90
80

P = 0.59

70
60
50
40

P = 0.01

P = 0.50

30
20
10
0
Before

After
Budesonide

Before

After

0.9% normal saline

Figure 2. Percent of neutrophils in the sputum of cystic fibrosis patients before and after
treatment.
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pg/mL
14000
12000
10000
8000

P = 0.44
P = 0.04

P = 0.35

6000
4000
2000
0

Before

After

Budesonide

Before

After

0.9% normal saline

Figure 3. Sputum IL-8 results of cystic fibrosis patients before and after treatment.

to the results of a metaanalysis in which FEV1 results of the
patients were compared at the end of 6 weeks, 3 months,
or 6 months of inhaled budesonide, fluticasone, or placebo
use and no statistically significant difference was found
between the drug and placebo groups (25). However, there
are also some retrospective studies showing a reduction in
the rate of FEV1 decline with the use of ICSs in CF patients
(27,28).
In CF, the dominant pathology in the lung is
inflammation generated primarily by failure to clear
microorganisms and the generation of a toxic proinflammatory local microenvironment (29). There is
chronic neutrophilic airway inflammation, typified
by increased membrane-bound and free neutrophil
elastase activity. Airway infection is a predominant and
persistent cause of neutrophilic inflammation. However,
inflammation can also be seen in asymptomatic children
with CF without lower airway colonization, and the
pathogenesis of noninfectious inflammation in these cases
is poorly understood (30). Airway inflammation in asthma
consists of mucosal, submucosal, and adventitial edema;
cellular infiltration, particularly by eosinophils, activated
helper T cells, mast cells, and sometimes neutrophils;
increased airway secretions, including secreted mucus,
desquamated lining cells, and intraluminal eosinophils;
capillary engorgement; hyperplasia of smooth muscle; and
deposition of excess collagen, particularly immediately
beneath the basement membrane of the epithelium (31).
BHR, which may be an indicator of airway inflammation,
has a well-known relationship with asthma. It can also be
seen in CF patients. Presence of BHR has been reported
in 40% of children with CF at the ages of 4–7 years and in
77% of patients at the ages of 8–18 years (32). ICSs are first
line antiinflammatory medications in asthma patients.
The use of an ICS for 2 months has been shown to cause

a permanent improvement in BHR (33). ICSs treat BHR
both by suppressing inflammation and also by preventing
persistent airway changes. Therefore, it can be proposed
that CF patients may benefit from treatment with ICSs.
van Haren et al. showed that BHR and symptoms in
adult CF patients benefit from budesonide (8). In our
study, although the number of the patients with BHR was
decreased following budesonide treatment, there was no
statistically significant difference in PC20FEV1 values of
patients before and after treatment. Our results were also
different from the results reported by Bisgaard et al., who
showed a decrease in BHR in response to budesonide in
CF patients. However, their patients were older than ours,
had chronic P. aeruginosa infection, and used ICS for a
longer duration (33). The response to indirect stimuli
such as hypertonic saline or exercise has been shown to
be different in CF from that in asthma. CF patients usually
bronchodilate after such challenges (34). In the light of
these findings, the mechanism leading to BHR in CF may
be different from that in asthma (24).
In terms of the symptom scores, there was no statistically
significant difference between the two groups at the end
of 8 weeks. Only one study showed an improvement in
cough and dyspnea at rest with the use of budesonide for
6 weeks in adult CF patients (8). However, no statistically
significant change in symptoms after ICS use has been
seen in other studies, just like in our study (25).
The ICS had no significant effect on inflammation and
oxidative damage intensity compared to the placebo in
our study. In a previous study performed by Dauletbaev
et al., 3 weeks of fluticasone therapy had no evident effect
on oxidative burst of sputum cells in adult CF patients
(35). There is conflicting evidence on the in vitro effect of
steroids on the oxidative burst of cells. In some studies, the
use of steroids has been reported to suppress the formation
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of oxygen radicals; however, some studies have found no
difference in the production of oxygen radicals (36,37).
Both our results and the results reported by Dauletbaev
et al. suggest that the use of ICSs in CF patients who are
known to be sensitive and prone to oxidative stress should
be approached cautiously. The significant decrease in MDA
levels in both groups in our study may point to an effect
of 0.9% normal saline on MDA. Similarly, an increase in
the levels of epithelial lining fluid glutathione, which is a
protective CFTR-dependent thiol against oxidative injury,
has been seen with 0.9% normal saline in an animal study
(38).
Induced sputum is a noninvasive technique to collect
cellular and soluble material from airways and its results
are similar to those of spontaneously expectorated sputum
in inflammatory measures (26). Osika et al. demonstrated
increased levels of neutrophil, IL-8, and TNF-α in the
sputum of CF patients and a reduction in TNF-α levels with
inhaled steroids (39). However, Balfour-Lynn et al. found
no significant effect of inhaled fluticasone on sputum IL-8,
TNF-α and neutrophil elastase levels (10). Similar to the
results reported by Wotzac et al., who showed a decrease in
BAL neutrophil counts with 2 months of beclomethasone
dipropionate treatment in 12 children with CF (9), the
percent of neutrophils in sputum decreased significantly
in the budesonide group in our study. Patients in the
budesonide group had higher WBC counts in sputum at
baseline and following treatment it significantly decreased
in the same group. IL-8 level in the sputum samples
increased significantly in the budesonide group. We
found a small but significant increase in an inflammatory
cytokine level; however, sputum is not homogeneous and
each cough brings sputum from a different part of the lung.
It is also difficult to analyze the sputum of CF patients due
to its viscosity (10). Furthermore, cytokine concentrations
in the sputum may be variable over time even in the same
patient without a change in the clinical status or pulmonary
function (40). IL-8 can also be produced by many different
cells and IL-8 level in the sputum can increase with the
increased number of epithelial cells. Therefore, caution
must be exercised while evaluating sputum IL-8 as an
inflammatory cytokine in CF (10). Furthermore, epithelial
cells exposed to P. aeruginosa produce IL-8, leading to
increased amounts of IL-8 in the lungs of patients with
P. aeruginosa infection (41). The increased number of
patients colonized with Pseudomonas in the budesonide
group in our study may also be a reason for the significant
increase in IL-8 levels in this group.
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In addition to studies investigating the effect of ICSs
in CF patients, Balfour-Lynn et al. evaluated the safety of
withdrawal of ICS and found no difference in terms of
time to first exacerbation, lung function, or antibiotic or
rescue bronchodilator use. They concluded that it appears
safe to consider stopping ICS in CF patients (42).
Since the inflammation in the lungs plays an important
role in the pathogenesis of CF, ICS treatment seems like
a good idea theoretically. However, adequate evidence is
needed before prescribing this therapy to CF patients. In
this study, we could not find any significant effect of the
ICS in any clinical or laboratory parameters. The reason
for this may be the inability of the ICS to pass through
the viscous mucus barrier found in the CF airways. The
ability of the inhaled drugs to reach the lungs depends
on the severity of the lung disease and the device and the
technique used to administer the drug. Different results
may be obtained by administering ICS from different ways
with different devices in different amounts. The nature of
the airway inflammation in CF also may play an important
role in terms of treatment response. In CF, inflammation
is predominantly neutrophilic and corticosteroids are
not found to be effective in conditions with neutrophilic
inflammation such as acute bronchiolitis (43). Steroids
have been shown to prolong neutrophil survival by
inhibiting apoptosis, and so they might even promote
inflammation in CF airways (25,44).
According to the results of this study and the others
in the literature, there is not enough data to suggest
the routine use of ICS in the treatment of CF; however,
withdrawal in those already taking them has been shown
to be safe. The authors of a recent review recommended
that the use of ICSs should be restricted to those with
symptomatic wheezing and in whom benefit has been
proven (45).
Lack of double-blinding is a limitation of our study. We
performed a single-blinded study due to nonavailability of
0.9% normal saline in a similar vial as budesonide. The
increased number of patients colonized with Pseudomonas
in the budesonide group compared to the placebo group
can also be a confounding factor while comparing the
results, especially the IL-8 levels. Inclusion of a small
number of subjects may also limit the generalization of the
results.
Although there was a significant decrease in the
percentage of neutrophils in sputum with nebulized
budesonide in children with CF, 8 weeks of 2 mg/day
nebulized budesonide was not effective in improving
BHR, oxidative status, or clinical or other inflammatory
parameters in children with CF.
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